» Articles » PMID: 30269936

Metabolome Analysis for Investigating Host-gut Microbiota Interactions

Overview
Specialty General Medicine
Date 2018 Oct 2
PMID 30269936
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Dysbiosis of the gut microbiome is associated with host health conditions. Many diseases have shown to have correlations with imbalanced microbiota, including obesity, inflammatory bowel disease, cancer, and even neurodegeneration disorders. Metabolomics studies targeting small molecule metabolites that impact the host metabolome and their biochemical functions have shown promise for studying host-gut microbiota interactions. Metabolome analysis determines the metabolites being discussed for their biological implications in host-gut microbiota interactions. To facilitate understanding the critical aspects of metabolome analysis, this article reviewed (1) the sample types used in host-gut microbiome studies; (2) mass spectrometry (MS)-based analytical methods and (3) useful tools for MS-based data processing/analysis. In addition to the most frequently used sample type, feces, we also discussed others biosamples, such as urine, plasma/serum, saliva, cerebrospinal fluid, exhaled breaths, and tissues, to better understand gut metabolite systemic effects on the whole organism. Gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and capillary electrophoresis-mass spectrometry (CE-MS), three powerful tools that can be utilized to study host-gut microbiota interactions, are included with examples of their applications. After obtaining big data from MS-based instruments, noise removal, peak detection, missing value imputation, and data analysis are all important steps for acquiring valid results in host-gut microbiome research. The information provided in this review will help new researchers aiming to join this field by providing a global view of the analytical aspects involved in gut microbiota-related metabolomics studies.

Citing Articles

Medicinal Cannabis and the Intestinal Microbiome.

Vitetta L, Nation T, Oldfield D, Thomsen M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770543 PMC: 11678570. DOI: 10.3390/ph17121702.


Comprehensive plasma metabolomics analysis of berberine treatment in ulcerative colitis rats by LC-MS/MS.

Feng B, Su L, Yang Y, Liu R, Zhang Y, Xin L Front Chem. 2024; 12:1518110.

PMID: 39722837 PMC: 11668600. DOI: 10.3389/fchem.2024.1518110.


A Comparison of Digestive Strategies for With Different Diet Compositions: Digestive Enzyme Activities, Gut Microbiota, and Metabolites.

Wang Z, Wu R, Yang Y Ecol Evol. 2024; 14(12):e70751.

PMID: 39717646 PMC: 11663733. DOI: 10.1002/ece3.70751.


Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes.

Yan J, Yang L, Ren Q, Zhu C, Du H, Wang Z Front Immunol. 2024; 15:1471273.

PMID: 39669573 PMC: 11634861. DOI: 10.3389/fimmu.2024.1471273.


The Gut Microbiota Impacts Gastrointestinal Cancers through Obesity, Diabetes, and Chronic Inflammation.

Rumyantsev K, Polyakova V, Sorokina I, Feoktistova P, Khatkov I, Bodunova N Life (Basel). 2024; 14(10).

PMID: 39459519 PMC: 11509742. DOI: 10.3390/life14101219.